Why the study?
Does a highly-sensitive cardiac troponin I (hsTnI) assay improve the predictive ability for hypertrophic cardiomyopathy compared to a contemporary troponin I assay in a screening population?
Population
107 consecutive hypertrophic cardiomyopathy sufferers and their relatives
Comparison
Highly-sensitive cardiac troponin I (hsTnI) assay vs Contemporary troponin I (cTnI) assay
Design
Case-control
Authors
Loading...
hsTnI does not significantly improve HCM discrimination over cTnI; leaves open troponin's role in screening at-risk populations.
Does a highly-sensitive cardiac troponin I (hsTnI) assay improve the predictive ability for hypertrophic cardiomyopathy compared to a contemporary troponin I assay in a screening population?
Both contemporary and highly-sensitive troponin I assays show a graded, positive association with cardiac muscle mass in persons at risk of HCM, though hsTnI did not significantly improve screening discrimination over cTnI.
McGorrian et al. (2013) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: